MetaVia Inc.
MTVA
Clasificación en acciones
#32894
Headquartered in Cambridge, Massachusetts, MetaVia Inc. operates as a... Headquartered in Cambridge, Massachusetts, MetaVia Inc. operates as a clinical-stage biotechnology company with a core focus on discovering and commercializing novel pharmaceutical solutions for cardiometabolic disorders. Its leading investigational drug, DA-1241, a unique G-Protein-Coupled Receptor 119 agonist, is currently undergoing Phase 2a clinical trials for metabolic dysfunction-associated steatohepatitis (MASH). This follows the successful completion of Phase 1 trials for type 2 diabetes mellitus (T2DM), and the compound holds promise for use as both a standalone therapy and in combination treatments. Another significant asset, DA-1726, an innovative oxyntomodulin analogue that functions as a dual agonist for GLP-1 and glucagon receptors, is presently in preclinical development specifically for treating obesity. MetaVia's broader therapeutic pipeline also includes ANA001, a distinct oral niclosamide formulation intended for moderate COVID-19 patients; NB-01, designed to address painful diabetic neuropathy; NB-02, targeting cognitive impairment; and Gemcabene, for the management of dyslipidemia. The company engages in strategic partnerships, notably a licensing agreement with Pfizer Inc. for the research, development, manufacturing, and commercialization of Gemcabene. Additionally, a joint research collaboration with Dong-A ST and ImmunoForge supports the advancement of DA-1726. The entity adopted its current name, MetaVia Inc., in November 2024, transitioning from its former identity as NeuroBo Pharmaceuticals, Inc.
Precio por acción
$1.28
Última sincronización: 2026-10-20
Capitalización bursátil
$8.43M
Cambio (1 día)
4.07%
Cambio (1 año)
-21.47%
País
US
Comercio MetaVia Inc. (MTVA)
Categoría
Healthcare
Número de acciones en circulación de MetaVia Inc. (MTVA)
Número de acciones en circulación al June 2026: 5.93B
Según los últimos informes financieros y el precio de las acciones de MetaVia Inc., el número actual de acciones en circulación es 5.93B. Al final de December 2023, la empresa tenía 5.07M acciones en circulación. El número de acciones en circulación generalmente se ve afectado por divisiones de acciones y recompras.
Historial de acciones en circulación de MetaVia Inc. (MTVA) desde 2014 hasta 2026
Acciones en circulación al final de cada año
| Año | Acciones en circulación | Cambiar |
|---|---|---|
| 2026 (TTM) | 5.93B | 7,547.03% |
| 2024 | 77.57M | 1,430.30% |
| 2023 | 5.07M | 1,475.68% |
| 2022 | 321.70K | 233.61% |
| 2021 | 96.43K | 42.71% |
| 2020 | 67.57K | 221.77% |
| 2019 | 21.00K | 18.56% |
| 2018 | 17.71K | 28.37% |
| 2017 | 13.80K | 78.15% |
| 2016 | 7.75K | 9.58% |
| 2015 | 7.07K | 0.00% |
| 2014 | 7.07K | 0.00% |
Acciones en circulación de empresas similares o competidores
| Empresa | Acciones en circulación | Diferencia | País |
|---|---|---|---|
| 253.90M | -95.72% |
US
|
|
| 396.00M | -93.32% |
US
|
|
| 478.91M | -91.93% |
AU
|
|
| - | - |
CH
|
|
| 62.19M | -98.95% |
NL
|
